What people on Wegovy actually find — the real picture

You've just been prescribed Wegovy, here's what the first few months tend to feel like

Picture this: it's a Tuesday evening and you're standing in the kitchen. You've eaten roughly half what you normally would and you're not performing willpower, you're just not that hungry. That's one of the things people on Wegovy report most consistently, and it's the medicine working as it's supposed to. Semaglutide activates GLP-1 receptors that influence appetite and slow the rate at which food leaves the stomach, so fullness arrives earlier and lingers longer.

The first pen contains the starting dose. That dose is deliberately low, its job is to let your body adjust rather than to produce immediate dramatic weight loss. Most people don't notice much happening in week one or two, which leads to the most common early misconception: that the medicine isn't working. It is. The therapeutic effect builds with the dose, which a prescriber increases gradually over several months.

Side effects in this early phase are mostly gastrointestinal, nausea is the one people mention most, along with loose stools, constipation, and indigestion. These are typically mild to moderate and ease off as the dose settles. The NHS medicines page for semaglutide covers what to expect in clear terms and is worth reading before you start.

For a closer look at the timeline of when weight change tends to begin, the page on when people start losing weight on Wegovy goes through this in more detail.

What the numbers say about how much weight people lose, and why that varies

The headline figure from the STEP 1 clinical trial is around 15% average body weight reduction over 68 weeks at the 2.4mg maintenance dose. That trial (published in the New England Journal of Medicine) involved nearly 2,000 adults with obesity or overweight and at least one weight-related condition, taking the injection alongside reduced-calorie eating and increased activity. Fifteen percent is an average; individuals ranged considerably above and below it.

Since then, a higher 7.2mg dose has been approved by the MHRA, with trial data reporting around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results considerably. The single-dose 7.2mg pen received MHRA approval in April 2026 for adults with a BMI of 30 or above.

What drives variation? Adherence to the dose schedule matters. So does the lifestyle support running alongside treatment, diet quality, protein intake, activity. Genetics play a role the medicine cannot override. And some people do not respond significantly regardless of adherence; why Wegovy doesn't work for everyone explores this honestly.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. BMI thresholds under UK guidance are 2.5 kg/m² lower for some ethnic backgrounds. For a fuller look at the evidence, the page on whether people lose weight on Wegovy pulls the trial data together in one place.

The things people on Wegovy don't always expect, and what to do about them

Beyond nausea, people describe a few things that catch them off guard. Food preferences sometimes shift, strong flavours or very rich meals that were previously enjoyable become unappealing. Some people find alcohol sits differently. Fatigue is reported in the early weeks, often coinciding with eating noticeably less.

More practically: eating habits need active management. Because appetite suppression can be so effective, some people eat too little protein without realising it, which matters for preserving muscle alongside fat loss. A dietitian or prescriber can advise on what to prioritise. The page on recipes for people on Wegovy has practical ideas for eating well during treatment.

On safety: the MHRA has highlighted acute pancreatitis as an infrequent but serious side effect of GLP-1 medicines. Severe stomach pain that extends to the back (especially with vomiting) needs urgent medical attention, not waiting to see if it passes. Any side effects you're concerned about should be discussed with your prescriber; suspected reactions can be reported at the MHRA's Yellow Card scheme.

People taking oral contraceptives alongside tirzepatide (Mounjaro) get specific advice about contraception during dose increases. For semaglutide, NHS guidance does not flag the same concern, but anyone with questions about their contraception should raise them with the prescriber.

Getting onto Wegovy in the UK, NHS, private, and what to ask before you start

NHS access to Wegovy runs through specialist weight management services under NICE guidance, and waiting lists in many areas are long. Private prescribing is the practical route for most people right now, no referral, no waiting list, but clinical assessment is still required. It is a prescription medicine; there is no way to obtain it lawfully without one.

Cost is a real consideration. The Wegovy price page covers what private treatment typically costs and what to look for in a provider. At nume, a named GPhC-registered prescriber (not automated software) reads every consultation the same day it arrives. Details of what that looks like are on our about us page.

The number of people now taking semaglutide across the UK is substantial and growing. How many people take semaglutide in the UK puts that in context. If you're weighing up whether to start, or wondering how Wegovy compares with other options, our treatment overview lays out the landscape clearly. When you're ready to have a clinical conversation, you can speak to our prescribers through a free consultation.